Lisa A. Bero
| Lisa Anne Bero | |
|---|---|
Lisa Bero at the 21st Annual Cochrane Colloquium, Quebec, September 2013
|
|
| Born |
Lisa Anne Bero 4 August 1958 New Orleans, Louisiana |
| Residence | Sydney, Australia |
| Alma mater | |
| Known for |
|
| Scientific career | |
| Fields |
|
| Institutions | |
| Thesis | The interaction of opioid and serotonergic systems regulation prolactin secretion in the developing rat (1987) |
Lisa Anne Bero, born 1958, is an academic who originally trained in pharmacology and went on to a career studying research integrity and how clinical and basic sciences are translated into clinical practice and health policy. She is Chair of Medicines Use and Health Outcomes at the University of Sydney. From 1991 until 2014, she was Professor in the Department of Clinical Pharmacy (School of Pharmacy) and in the Institute of Health Policy Studies (School of Medicine) at the University of California, San Francisco (UCSF), and is currently an adjunct professor there. She is also Chair of the World Health Organization (WHO) Essential Medicines Committee, Director of the WHO Collaborating Centre for Pharmaceutical Research and Science Policy, and Co-Chair of the Cochrane Collaboration. Bero has received multiple awards for her extensive mentoring of high school students to junior faculty.
Bero gained a Bachelor of Science in physiology and philosophy from Michigan State University in 1980. She was awarded a PhD in pharmacology and toxicology from Duke University in 1987. She received a National Institute on Drug Abuse postdoctoral fellowship on the molecular basis of opiate addiction, but left basic research for health policy when she received a Pew Health Policy Fellowship in 1988, which included training in epidemiology.
A fellowship from the Pew Charitable Trust enabled her to make a transition from the basic sciences to health policy. Bero explained the impact of this on her career: "I do a lot of work on government committees and international committees. Had it not been for the Pew program I would have been a much more typical academic." She had a particular interest in the evidence basis for health practice and policy, often in controversial areas. She began researching both the evidence to improve prescribing, and the influence of the pharmaceutical industry on drug research, and going on to an interest in the tobacco industry's influence on research and policy. Her areas of research have since also included methods for assessing bias and quality of research and scientific publications, and the dissemination and policy implications of research.
...
Wikipedia